In vitro assessment of ceftazidime-avibactam combined with aztreonam for mitigating antimicrobial resistance in clinical isolates of multidrug-resistant Gram-negative bacilli
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20254154Keywords:
AMR, Avibactam/Aztreonam, Aztreonam, Carbapenem-resistant, Ceftazidime-avibactam, Ceftazidime- synergy testing, Enterobacterales, ESBL, Gram-negative bacilli, MDR isolates, Non-fermentersAbstract
Background: Antimicrobial resistance (AMR) represents a major global public health threat, with increasing MDR infections caused by Gram-negative such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter spp. The limited antibiotic pipeline and ineffective treatments have necessitated the development of novel drug combinations. Among these, the combination of ceftazidime-avibactam with aztreonam has shown promise, particularly against serine-β-lactamase and metallo-β-lactamase producing strains that are resistant to conventional therapeutics.
Methods: Identification of isolates was done by routine biochemical testing; AST was determined by Kirby-Bauer disc diffusion, interpreted by CLSI guidelines. MDR, XDR, PDR were characterized. ESBL producers and carbapenem resistant strains were detected phenotypically using CLSI guidelines. In vitro synergy of ceftazidime-avibactam plus aztreonam was assessed by broth disc elution, following CLSI recommendations.
Results: Of 183 isolates of gram-negative bacilli, Escherichia coli (n=67), Klebsiella pneumoniae (n=72), Pseudomonas aeruginosa (n=29) and Acinetobacter spp. (n=15) in which MDR 68.65% was reported in Escherichia coli and 66.66% of XDR was reported in Klebsiella pneumoniae. ESBL was detected in 68 of 80 Enterobacterales, while 90 of 150 tested GNB were carbapenem resistant; Klebsiella pneumoniae contributed highest numbers. The combination of ceftazidime-avibactam with aztreonam yielded synergistic activity in 83.4% of all GNB isolates. Within carbapenem-resistant Enterobacterales, susceptibility to the combination was 97.2%, contrasting with only 15.7% susceptibility among carbapenem-resistant non-fermenters. Resistance to the combination was especially high among XDR and PDR Acinetobacter spp. and Pseudomonas aeruginosa.
Conclusions: The combination of ceftazidime-avibactam with aztreonam demonstrates strong in vitro synergy and enhanced susceptibility against MDR and carbapenemase-producing Enterobacterales especially Klebsiella pneumoniae suggesting clinical promise where conventional drugs fail. However, limited efficacy was observed against non-fermenter groups, underscoring the need for continuing resistance surveillance and further therapeutic innovation in multidrug-resistant non-fermenters.
Metrics
References
World Health Organization. Antimicrobial resistance. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Accessed on 1 July 2025.
World Health Organization. Global antimicrobial resistance forum launched to help tackle common threat to planetary health. 2023. Available from: https://www.who.int/news-room/articles-detail/global-antimicrobial-resistance-forum-launched-to-help-tackle-common-threat-to-planetary-health. Accessed on 2 July 2025.
Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018;4(3):482-501. DOI: https://doi.org/10.3934/microbiol.2018.3.482
Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, et al. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare. 2023;11(13):1946. DOI: https://doi.org/10.3390/healthcare11131946
Oliveira J, Reygaert WC. Gram-Negative Bacteria. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.
Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther. 2015;40(4):277-83.
Gargate N, Laws M, Rahman KM. Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria. npj Antimicrob Resist. 2025;3(1):50. DOI: https://doi.org/10.1038/s44259-025-00123-1
World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. 2017. Available from: https://www.who.int/publications/ i/item/WHO-EMP-IAU-2017.12. Accessed on 1 July 2025.
Bognar B, Spohn R, Lazar V. Drug combinations targeting antibiotic resistance. npj Antimicrob Resist. 2024;2:29. DOI: https://doi.org/10.1038/s44259-024-00047-2
CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests, 13th ed. CLSI document M02-A13. Clinical and Laboratory Standards Institute; 2024.
CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 34th ed. CLSI supplement M100-S34. Clinical and Laboratory Standards Institute; 2024.
CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 35th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2025.
Lal A, Kumar HKS, Janardhanan J, Gopal A. Detection of Polymyxin B resistance in Enterobacterales by broth disk elution method. Int J Community Med Public Health. 2023;10:2165-70. DOI: https://doi.org/10.18203/2394-6040.ijcmph20231698
Sivadas A, Sajeev A, KS HK, Krishnan S. Detection of colistin susceptibility in extended spectrum β lactamases positive Klebsiella pneumoniae and Escherichia coli clinical isolates by broth disc elution method. Int J Res Med Sci. 2024;12(4):1203. DOI: https://doi.org/10.18203/2320-6012.ijrms20240844
Shahid M, Malik A, Sheeba. Multi-drug resistant Pseudomonas aeruginosa strains harbouring R-plasmids and AmpC β-lactamases isolated from hospitalised burn patients in a tertiary care hospital of North India. FEMS Microbiol Lett. 2003;228(2):181-6. DOI: https://doi.org/10.1016/S0378-1097(03)00756-0
Tewari R, Chopra D, Wazahat R, Dhingra S, Dudeja M. Antimicrobial susceptibility patterns of an emerging multidrug resistant nosocomial pathogen: Acinetobacter baumannii. Malays J Med Sci. 2018;25(3):129-34. DOI: https://doi.org/10.21315/mjms2018.25.3.13
Shokri D, Rabbani Khorasgani M, Zaghian S, Fatemi SM, Mohkam M, Ghasemi Y, et al. Determination of acquired resistance profiles of Pseudomonas aeruginosa isolates and characterization of an effective bacteriocin-like inhibitory substance (BLIS) against these isolates. Jundishapur J Microbiol. 2016;9(8):e32795. DOI: https://doi.org/10.5812/jjm.32795
Pattnaik D, Panda SS, Singh N, Sahoo S, Mohapatra I, Jena J. Multi-drug resistant, extensively-drug resistant and pan drug-resistant gram negative bacteria at a tertiary care centre in Bhubaneswar. Int J Community Med Public Health. 2019;6:567-72. DOI: https://doi.org/10.18203/2394-6040.ijcmph20190170
Kumar HKS, Asina PA, Theckel PG, Divakaran B, Sathar S, Asalatha R, Remya VS. Prevalence of multidrug resistant uropathogens isolated from different age groups in South-India: a cross-sectional study. Int J Res Med Sci. 2022;10(4):905-12. DOI: https://doi.org/10.18203/2320-6012.ijrms20220984
Verma G, Singh N, Smriti S, Panda SS, Pattnaik D, Tripathy S, et al. Modified carbapenem inactivation method and ethylenediaminetetraacetic acid (EDTA)-carbapenem inactivation method for detection of carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa. Cureus. 2024;16(6):e63340. DOI: https://doi.org/10.7759/cureus.63340
Rajshekar D, Sujatha SR, Karthik MVSK, Raveendran S. Evaluation of phenotypic carbapenem inactivation methods among carbapenem resistant gram-negative bacteria isolated from blood culture specimens and their synergy testing. Indian J Microbiol Res 2024;11(3):175-179 DOI: https://doi.org/10.18231/j.ijmr.2024.032
Biswal D, Narayan M, Mohapatra S, Gautam H, Dhawan B, Das BK, et al. Rapid identification of carbapenemases and in vitro synergy testing of ceftazidime-avibactam with aztreonam in extensively drug-resistant gram-negative pathogens: Establishing the realm of promise. Indian J Med Microbiol. 2025;55:100834. DOI: https://doi.org/10.1016/j.ijmmb.2025.100834
Rajan R, Rao AV, Kumar MS. Ceftazidime avibactam/aztreonam combination synergy against carbapenem-resistant Gram negative isolates: in vitro study. Curr Med Res Pract. 2024;14:16-21. DOI: https://doi.org/10.4103/cmrp.cmrp_189_23
Downloads
Published
How to Cite
Issue
Section
